本人李梦涓，已充分了解并同意由提名人北京热景生物技术股份 有限公司董事会提名为北京热景生物技术股份有限公司第四届董事 会独立董事候选人。本人公开声明，本人具备独立董事任职资格，保 证不存在任何影响本人担任北京热景生物技术股份有限公司独立董 事独立性的关系，具体声明并承诺如下： 北京热景生物技术股份有限公司 独立董事候选人声明与承诺 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法 规、部门规章及其他规范性文件，具有五年以上法律、经济会计、财 务、管理等履行独立董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司 规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 （如适用）； （三）中国证监会《上市公司独立董事管理办法》和上海证券交 易所自律监管规则有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定（如适用）； （五）中共中央组织部《关于进一步规范党政领导干部在企业兼 ...

北京热景生物技术股份有限公司董事会提名委员会 经审阅公司第四届董事会独立董事候选人宋云锋先生、徐小舸女士、李梦涓 女士的个人履历等相关资料,上述独立董事候选人未持有公司股份,与公司控股 股东、实际控制人、持有公司 5%以上股份的股东及其他董事、监事、高级管理 人员之间不存在关联关系,不存在《公司法》及《公司章程》规定的不得担任独 立董事的情形;不存在被中国证监会确定为市场禁入者且尚在禁入期的情形,也 不存在被证券交易所公开认定不适合担任上市公司独立董事的情形,不属于失信 被执行人,符合《公司法》《上海证券交易所科创板股票上市规则》《上市公司独 立董事管理办法》等相关法律法规、规范性文件及《公司章程》规定的任职资格 和独立性要求。 上述独立董事候选人具有丰富的专业知识,熟悉相关法律、行政法规、规章 与规则,其任职资格、教育背景、工作经历、业务能力符合公司独立董事任职要 求。 综上,我们同意提名宋云锋先生、徐小舸女士、李梦涓女士为公司第四届董 事会独立董事候选人,并同意将该事项提交公司董事会审议。 北京热景生物技术股份有限公司董事会提名委员会 关于第四届董事会独立董事候选人任职资格的审查意见 根据《中华人民共和国 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-044 北京热景生物技术股份有限公司 关于董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上述非职工代表董事将与公司职工代表大会选举出的 1 名职工代表董事共 同组成公司第四届董事会，公司第四届董事会董事自公司 2025 年第三次临时股 东大会审议通过之日起就任，任期三年。 公司第三届董事会成员在任职期间勤勉尽责，为促进公司规范运作和持续发 展发挥了积极作用，公司对各位董事在任职期间为公司发展所做的贡献表示衷心 感谢！ 特此公告。 北京热景生物技术股份有限公司董事会 附件： 北京热景生物技术股份有限公司（以下简称"公司"）第三届董事会即将届 满。根据《中华人民共和国公司法》 （以下简称《公司法》）、 《北京热景生物技术 股份有限公司章程》等有关规定，公司于 2025 年 6 月 16 日召开第三届董事会第 二十九次会议，审议通过了《关于选举第四届董事会非独立董事的议案》和《关 于选举第四届董事会独立董事的议案》。 经公司董事会提名，并经公 ...

红星资本局6月15日消息，创新药板块持续演绎下，已有公募基金产品年内收益率超过100%。 截至6月13日收盘，汇添富旗下重仓港股创新药的汇添富香港优势精选，年内总收益达到103.67%，暂时位居基金业绩榜首。据wind统计，距离A股上半年收 官还剩半个月时间，把握住创新药行情的多只基金，年内业绩已经大幅跑赢其他赛道产品。 红星资本局注意到，随着创新药基金"霸屏"收益榜，一则"电子研究群也在聊创新药"的消息引发热议，不少投资者也在社交平台询问"还能上车吗？"对此， 基金经理内部也有不同观点。 医药主题基金"苦尽甘来" 年内首只"翻倍基"出炉 今年以来，历经四年深度调整的医药板块迎来曙光，不少医药主题基金表现亮眼。红星资本局根据wind数据不完全统计发现，截至6月13日，260只（仅计算 初始基金，下同）名称中带有"医"或"药"的基金中，228只年内取得正收益，占比为87.69%，有88只收益率超过30%，63只收益率过40%。 其中，创新药主题基金不仅领涨整个医药板块，而且领涨市场。6月13日晚公布的基金净值数据显示，由张韡管理的汇添富香港优势精选QDII基金，年内收 益率达到103.67%，成为年内首只"翻倍 ...

A股创新药板块走势分化，赛升药业涨超11%，千红制药涨超8%，百洋医药、悦康药业均涨超7%；荣 昌生物跌超7%，润都股份跌超6%，热景生物跌超5%。 订阅A股市场资讯 +订阅 ...

Core Viewpoint - The company, 热景生物, has seen significant stock price increases due to its investments in innovative pharmaceutical companies, but it faces ongoing losses in its core in vitro diagnostics business, raising concerns about future profitability from these investments [1][5]. Group 1: Stock Performance and Market Sentiment - On June 9, the stock price of 热景生物 surged by 18.15%, reaching a peak of 164.28 yuan before closing down 1.95% on June 10 [2]. - The stock has increased by 155.5% year-to-date and has seen a staggering 5.8-fold increase since the "924" market rally last year, ranking among the top five performers in the A-share market [1][2]. - The company’s small market capitalization and high volatility have attracted speculative trading, particularly in the context of the innovative drug theme [2]. Group 2: Investment in Innovative Pharmaceuticals - 热景生物 is pursuing a dual strategy of "diagnostics + innovative drugs," focusing on antibody and nucleic acid drugs through strategic investments in innovative pharmaceutical companies [3]. - As of the end of Q1 this year, the company had invested 312 million yuan in long-term equity investments, with a reported loss of 43.61 million yuan from these investments last year [3]. - The company has invested in several innovative drug firms, with one focusing on original antibody drug development recently completing a 300 million yuan Series A financing round [3][4]. Group 3: Financial Performance and Challenges - The core diagnostics business of 热景生物 has been experiencing significant losses, with a dramatic decline in revenue and profit following the peak sales of COVID-19 antigen test kits [5][6]. - In 2021, the company reported a revenue of 5.063 billion yuan from COVID-19 tests, but this dropped to 541 million yuan in 2023, a decline of nearly 85% [5]. - The company reported a net loss of 593.3 million yuan in 2023, continuing a trend of losses over seven consecutive quarters [1][6]. Group 4: Shareholder Actions - Following the surge in stock price, major shareholders, including 同程热景, have begun to cash out, with a total reduction of 214 million yuan in shares [1][6]. - The controlling shareholder, 林长青, is associated with 同程热景, indicating a coordinated exit strategy among major stakeholders [6].

Core Viewpoint - On June 9, the Shanghai Composite Index rose by 0.43%, with institutional investors appearing on the trading lists of 21 stocks, net buying 11 and net selling 10 [1][2]. Institutional Trading Summary - Institutional special seats net bought the most in Kuaibao Tong, which closed at the daily limit with a turnover rate of 34.75% and a transaction amount of 2.396 billion [2][5]. - Other notable stocks include Hot Scene Biology, which rose by 18.15% with a turnover rate of 6.41% and a transaction amount of 902 million, and Changshan Pharmaceutical, which also closed at the daily limit with a turnover rate of 7.75% and a transaction amount of 3.532 billion [2][5][6]. Market Performance - The average increase of stocks with institutional net buying was 14.37%, outperforming the Shanghai Composite Index [3]. - Stocks like Kangli Source and Changshan Pharmaceutical showed strong performance, closing at the daily limit [3]. Net Selling Summary - The stock with the highest net selling by institutions was Yuyin Co., with a net selling amount of 1.400846 billion due to a turnover rate of 54.21% [3][6]. - Hengbao Co. also saw significant net selling, with a net selling amount of 1.134366 billion [3][6]. Deep and Hong Kong Stock Connect - On June 9, 10 stocks on the trading list had appearances from the Deep and Hong Kong Stock Connect, with net buying in stocks like Changshan Pharmaceutical and Jinlongyu [7][8]. - The net buying amounts for these stocks were 1.04985 billion and 568.761 million, respectively [8].

热景生物6月9日龙虎榜 6月9日热景生物（688068）收盘价161.15元，收盘上涨18.15%，全天换手率6.41%，振幅24.46%，成交 额9.02亿元。科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交3.79亿元， 其中，买入成交额为2.37亿 元，卖出成交额为1.42亿元，合计净买入9503.95万元。具体来看，今日上榜的前五大买入营业部中，有 3家机构专用席位现身，即买一、买四、买五，买入金额分别为8867.62万元、3117.17万元、2460.83万 元，营业部合计买入9260.57万元。卖出营业部中，有1家机构专用席位现身，即卖二，卖出金额分别为 3442.21万元，营业部合计卖出1.08亿元。买卖金额相抵，机构专用席位今日净买入该股1.10亿元。 资金流向方面，该股今日全天主力资金净流入5174.91万元。（数据宝） | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 机构专用 | 8867.62 | | 国盛证券有限责任公司深圳粤海街道证券营业部 | 4746.58 | | 高盛(中国)证 ...

中国经济网北京6月6日讯热景生物(688068.SH)昨日晚间披露关于股东减持计划完成暨减持股份结果公告。 热景生物于2025年3月22日披露了《北京热景生物技术股份有限公司股东减持股份计划公告》，股东青岛同程热景企业管理 咨询合伙企业(有限合伙)(以下简称"同程热景")因自身资金需求，计划通过集中竞价、大宗交易方式减持所持有公司股份合 计不超过1,800,000股，占公司当时总股本的1.9465%。 热景生物的控股股东、实际控制人、董事长、总经理林长青系同程热景的执行事务合伙人和普通合伙人。根据热景生物 2024年年报显示，林长青直接持有公司23.4469%的股权，通过同程热景间接持有公司0.9640%的股权，为公司的实际控制 人。 2024年，热景生物营业总收入为51,089.06万元，同比减少7.62%；归属于母公司所有者的净利润-17,923.07万元，2023年同 期为2,851.62万元；归属于母公司所有者的扣除非经常性损益的净利润为-24,315.82万元，2023年同期-5,819.66万元。 热景生物于2019年9月30日在上交所科创板上市，发行数量为15,550,000股(无老股转让)，发 ...

Group 1 - Aike Technology (688092.SH) shareholders plan to reduce their holdings by up to 826,906 shares, accounting for 1.00% of the total share capital within three months after 15 trading days from the announcement [1] - Aike Cyber (688719.SH) executives plan to reduce their holdings by up to 2.1927% of the total share capital, totaling 2,530,000 shares within three months after 15 trading days from the announcement [1] - Anpeilong (301413.SZ) shareholders plan to reduce their holdings by up to 2,952,058 shares, representing 3% of the total share capital [1] Group 2 - Chaohongji (002345.SZ) shareholders plan to reduce their holdings by up to 26,655,380 shares, accounting for 3% of the total share capital within three months after 15 trading days from the announcement [2] - Chunguang Technology (603657.SH) plans to reduce its holdings by up to 1,000,000 shares, representing 0.73% of the total share capital [2] - Dahongli (300865.SZ) controlling shareholder plans to reduce his holdings by 136,150 shares, accounting for 1.4230% of the total share capital [2] Group 3 - Electric Link Technology (300679.SZ) executives plan to reduce their holdings by specified amounts, with individual reductions not exceeding 15,000 to 78,000 shares [2] - Guangge Technology (688450.SH) shareholders plan to reduce their holdings by a total of 990,000 shares, representing 1.50% of the total share capital [2] - Guorui Technology (300600.SZ) shareholders plan to reduce their holdings by 8,827,034 shares, accounting for 3% of the total share capital [3] Group 4 - Hailier (603639.SH) shareholders plan to reduce their holdings by up to 1,200,000 shares, representing 1% of the total share capital [3] - Haotong Technology (301026.SZ) executives plan to reduce their holdings by specified amounts, with individual reductions not exceeding 20,965 to 47,250 shares [3] - Huamao Logistics (603128.SH) executives have reduced their holdings by 272,000 shares, while other executives did not reduce their holdings [3] Group 5 - Jiamei Packaging (002969.SZ) shareholders plan to reduce their holdings by a total of 9,483,239 shares, accounting for 1.00% of the total share capital [4] - Jiangsu Boyun (301003.SZ) shareholders plan to reduce their holdings by up to 971,333 shares through centralized bidding and 1,942,666 shares through block trading [4] - Jinchicken Co., Ltd. (300798.SZ) shareholders plan to reduce their holdings by 14,000,000 shares, representing 2.99% of the total share capital [4] Group 6 - Jingfang Technology (603005.SH) shareholders plan to reduce their holdings by up to 13,043,400 shares, accounting for 2% of the total share capital [5] - Jingjin Electric (688280.SH) shareholders plan to reduce their holdings through centralized bidding or block trading [5] - Kolon New Materials (920098) shareholders have not implemented reductions, while another shareholder reduced holdings by 651,667 shares, representing 0.8014% of the total share capital [5] Group 7 - Liangpinpuzi (603719.SH) shareholders plan to reduce their holdings by 4,010,000 shares, accounting for 1% of the total share capital [6] - Mike Audi (300341.SZ) executives plan to reduce their holdings by 546,350 shares, representing 0.11% of the total share capital [6] - Pinwa Food (300892.SZ) shareholders reduced their holdings by 711,300 shares, accounting for 0.72% of the total share capital [6] Group 8 - Qiu Le Seed Industry (831087.BJ) shareholders plan to reduce their holdings by up to 3,300,000 shares, representing no more than 1.9975% of the total share capital [6] - Qiu Tianwei (300939.SZ) shareholders reduced their holdings by 1,100,000 shares, accounting for 0.93% of the total share capital [6] - Rejing Bio (688068.SH) shareholders plan to reduce their holdings by 1,800,000 shares, representing 1.9416% of the total share capital [7] Group 9 - Saike Xide (688338.SH) executives plan to reduce their holdings by specified amounts, with individual reductions not exceeding 250,000 to 235,000 shares [7] - Wancheng Group (300972.SZ) executives plan to reduce their holdings through centralized bidding [7] - Wentai Technology (600745.SH) shareholders plan to reduce their holdings by up to 24,891,577 shares through block trading and 12,445,788 shares through centralized bidding [7] Group 10 - Xiechuang Data (300857.SZ) executives plan to reduce their holdings by specified amounts, with individual reductions not exceeding 10,500 to 18,900 shares [8] - Xinhongze (002836.SZ) controlling shareholder reduced holdings by 1,895,300 shares, decreasing ownership from 63.74% to 62.91% [8] - Panda Dairy (300898.SZ) shareholders reduced their holdings by 884,470 shares, accounting for 0.7133% of the total share capital [8] Group 11 - Oat Technology (688312.SH) controlling shareholder plans to reduce holdings by up to 2,912,000 shares, representing no more than 2% of the total share capital [9] - Youningwei (301166.SZ) shareholders plan to reduce their holdings by 1,208,500 shares, accounting for 1.41% of the total share capital [9] - Yuhua Tian (300815.SZ) shareholders plan to reduce their holdings by up to 23,915,520 shares, representing no more than 6.00% of the total share capital [9] Group 12 - Zhangzidao (002069.SZ) shareholders plan to reduce their holdings by up to 7,111,000 shares, accounting for no more than 1% of the total share capital [9] - Zhishang Technology (301486.SZ) shareholders reduced their holdings by 1,245,300 shares, accounting for 0.9677% of the total share capital [10] - Zhongjing Electronics (002579.SZ) shareholders plan to reduce their holdings by up to 6,000,000 shares through centralized bidding or block trading [10]